To provide an accurate write-up, could you please clarify what mird237 2021 refers to?
Here is a detailed feature breakdown for the title:
2021 saw a surge in the development of selective kinase inhibitors for oncology. MIRD237 served as a key building block for the pyrimidine core in several PI3K and mTOR inhibitor candidates.
Here is a detailed synthesis of the key MIRD dosimetry and radioembolization developments relevant to 2021: 1. Key 2021 MIRD-Related Developments
Is "mird237" perhaps a pamphlet number or a specific radiopharmaceutical? If you confirm, I can look for that specific document.
Key Updates in MIRD 37 2021: The MIRD 37 2021 report includes several key updates, including:
Title: An Overview of MIRD 37 2021: Updates and Implications for Internal Radiation Dose Calculations
If the user intended a different context for MIRD237, such as a specific study, conference, or working group, they might need to provide additional details. However, based on the existing MIRD publications and the year 2021, I can focus on the MIRD Pamphlet No. 24 as the most plausible reference. Alternatively, if MIRD237 is part of another organization's nomenclature not related to SNMMI's MIRD, I would need more information. Given the constraints, I'll proceed with the assumption that MIRD237 2021 is a misinterpretation or mislabeling of the MIRD Pamphlet 24 from 2021, and develop the write-up around that document, explaining its importance and key points.